Peptide vaccine IPX for sarcoma, synovial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Sep 2023: Trial started, NCT06094101
  2. 23 Oct 2023: Trial registered, NCT06094101

The trials

NCT06094101: Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

State
Under way
Phase
Phase 1 and Phase 2
People
30 planned
Started
19 Sep 2023
Primary completion
Jun 2027
Arms
Peptide vaccination
Results
None posted
  1. 19 Sep 2023: Trial started
  2. 23 Oct 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.